The concept of innovative drugs in A-shares continued to strengthen, with BeiGene, InnoCare Pharma, and Jinbo Biopharma all setting historical highs. Kelun Pharmaceuticals, Ingenics, Zejing Pharmaceuticals, Huadong Medicine, and Hengrui Medicine were among the top gainers.